ADC Therapeutics SA has a consensus price target of $20.23, established from looking at the 43 latest analyst ratings. The last 3 analyst ratings were released from Guggenheim, RBC Capital, and HC Wainwright & Co. on March 28, 2024, March 14, 2024, and March 6, 2024. With an average price target of $9.33 between Guggenheim, RBC Capital, and HC Wainwright & Co., there's an implied 113.62% upside for ADC Therapeutics SA from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/28/2024 | ADCT | Buy Now | ADC Therapeutics | $4.37 | 151.76% | Guggenheim | Michael Schmidt | → $11 | Initiates | → Buy | Get Alert |
03/14/2024 | ADCT | Buy Now | ADC Therapeutics | $4.37 | 83.1% | RBC Capital | Gregory Renza | → $8 | Reiterates | Outperform → Outperform | Get Alert |
03/06/2024 | ADCT | Buy Now | ADC Therapeutics | $4.37 | 105.99% | HC Wainwright & Co. | Robert Burns | → $9 | Reiterates | Buy → Buy | Get Alert |
02/26/2024 | ADCT | Buy Now | ADC Therapeutics | $4.37 | 83.1% | RBC Capital | Gregory Renza | $6 → $8 | Maintains | Outperform | Get Alert |
02/20/2024 | ADCT | Buy Now | ADC Therapeutics | $4.37 | 105.99% | HC Wainwright & Co. | Robert Burns | $3 → $9 | Maintains | Buy | Get Alert |
11/20/2023 | ADCT | Buy Now | ADC Therapeutics | $4.37 | -31.34% | HC Wainwright & Co. | Robert Burns | $12 → $3 | Maintains | Buy | Get Alert |
11/09/2023 | ADCT | Buy Now | ADC Therapeutics | $4.37 | — | TD Cowen | Boris Peaker | — | Downgrade | Outperform → Market Perform | Get Alert |
11/08/2023 | ADCT | Buy Now | ADC Therapeutics | $4.37 | 37.32% | RBC Capital | Gregory Renza | $7 → $6 | Maintains | Outperform | Get Alert |
09/19/2023 | ADCT | Buy Now | ADC Therapeutics | $4.37 | 174.65% | HC Wainwright & Co. | Robert Burns | → $12 | Reiterates | Buy → Buy | Get Alert |
09/12/2023 | ADCT | Buy Now | ADC Therapeutics | $4.37 | 83.1% | RBC Capital | Gregory Renza | $9 → $8 | Maintains | Outperform | Get Alert |
08/10/2023 | ADCT | Buy Now | ADC Therapeutics | $4.37 | — | JP Morgan | Brian Cheng | — | Upgrade | Underweight → Neutral | Get Alert |
08/09/2023 | ADCT | Buy Now | ADC Therapeutics | $4.37 | 105.99% | RBC Capital | Gregory Renza | $10 → $9 | Maintains | Outperform | Get Alert |
07/25/2023 | ADCT | Buy Now | ADC Therapeutics | $4.37 | 174.65% | HC Wainwright & Co. | Robert Burns | → $12 | Reiterates | Buy → Buy | Get Alert |
07/11/2023 | ADCT | Buy Now | ADC Therapeutics | $4.37 | -54.23% | Morgan Stanley | Jeffrey Hung | $5 → $5 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
06/20/2023 | ADCT | Buy Now | ADC Therapeutics | $4.37 | 174.65% | HC Wainwright & Co. | Robert Burns | $20 → $12 | Maintains | Buy | Get Alert |
05/10/2023 | ADCT | Buy Now | ADC Therapeutics | $4.37 | 128.87% | RBC Capital | Gregory Renza | $12 → $10 | Maintains | Outperform | Get Alert |
04/24/2023 | ADCT | Buy Now | ADC Therapeutics | $4.37 | -54.23% | B of A Securities | Tazeen Ahmad | $7 → $2 | Downgrade | Neutral → Underperform | Get Alert |
02/13/2023 | ADCT | Buy Now | ADC Therapeutics | $4.37 | 174.65% | RBC Capital | Gregory Renza | $18 → $12 | Maintains | Outperform | Get Alert |
01/24/2023 | ADCT | Buy Now | ADC Therapeutics | $4.37 | 14.44% | Morgan Stanley | Matthew Harrison | $7 → $5 | Maintains | Equal-Weight | Get Alert |
The latest price target for ADC Therapeutics (NYSE: ADCT) was reported by Guggenheim on March 28, 2024. The analyst firm set a price target for $11.00 expecting ADCT to rise to within 12 months (a possible 151.76% upside). 17 analyst firms have reported ratings in the last year.
The latest analyst rating for ADC Therapeutics (NYSE: ADCT) was provided by Guggenheim, and ADC Therapeutics initiated their buy rating.
The last upgrade for ADC Therapeutics SA happened on August 10, 2023 when JP Morgan raised their price target to N/A. JP Morgan previously had an underweight for ADC Therapeutics SA.
The last downgrade for ADC Therapeutics SA happened on November 9, 2023 when TD Cowen changed their price target from N/A to N/A for ADC Therapeutics SA.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADC Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADC Therapeutics was filed on March 28, 2024 so you should expect the next rating to be made available sometime around March 28, 2025.
While ratings are subjective and will change, the latest ADC Therapeutics (ADCT) rating was a initiated with a price target of $0.00 to $11.00. The current price ADC Therapeutics (ADCT) is trading at is $4.37, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.